Condition
Thymidine Kinase 2 Deficiency
Total Trials
4
Recruiting
0
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03845712Phase 2Active Not RecruitingPrimary
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
NCT03639701Phase 1Active Not Recruiting
Treatment of TK2 Deficiency With Thymidine and Deoxycytidine
NCT05017818CompletedPrimary
A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency
NCT04581733Phase 3WithdrawnPrimary
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)
Showing all 4 trials